Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director · PRESIDENT AND CEO · 10% owner | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | Direct | 875,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 875,000 · Balance 875,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | IndirectBy Spouse | 240,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 240,000 · Balance 240,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:19 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001378550-26-000003 · form4-01052026_090159.xml · derivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:19 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 875,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001378550-26-000003 · form4-01052026_090159.xml · derivative · entry 1 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Stock · 875,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $14.49 | $724,345.00 |
DisclosureSEC source: 0001415889-25-022761 · form4-08222025_040804.xml · nonDerivative · entry 1 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,196,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $14.4869 and the range of prices were between $14.31 and $14.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 261,900 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000464 · form4-01032025_040132.xml · derivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 261,900 Underlying: Common Stock · 261,900 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 767,600 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000464 · form4-01032025_040132.xml · derivative · entry 1 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,600 Underlying: Common Stock · 767,600 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:20 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.67 | $583,525.00 |
DisclosureSEC source: 0001415889-24-029851 · form4-12192024_041201.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,098,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $11.6705, and the range of prices were between $11.56 and $11.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:20 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.67 | $583,575.00 |
DisclosureSEC source: 0001415889-24-029851 · form4-12192024_041201.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,297,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $11.6715 and the range of prices were between $11.56 and $11.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 23:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.16 | $658,155.00 |
DisclosureSEC source: 0001415889-24-029011 · form4-12112024_061201.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,148,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $13.1631, and the range of prices were between $12.94 and $13.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 23:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.17 | $658,265.00 |
DisclosureSEC source: 0001415889-24-029011 · form4-12112024_061201.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,246,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $13.1653, and the range of prices were between $12.94 and $13.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 22:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 11,876 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001415889-24-028678 · form4-12092024_101253.xml · derivative · entry 9 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 338,124 Underlying: Common Stock · 11,876 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 22:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 13,789 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001415889-24-028678 · form4-12092024_101253.xml · derivative · entry 8 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 20,684 Underlying: Common Stock · 13,789 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 22:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 11,876 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001415889-24-028678 · form4-12092024_101253.xml · derivative · entry 7 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,088,124 Underlying: Common Stock · 11,876 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 22:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 11,876 | $8.42 | $99,995.92 |
DisclosureSEC source: 0001415889-24-028678 · form4-12092024_101253.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,433,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 22:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 13,789 | $1.44 | $19,856.16 |
DisclosureSEC source: 0001415889-24-028678 · form4-12092024_101253.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,421,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 22:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 11,876 | $8.42 | $99,995.92 |
DisclosureSEC source: 0001415889-24-028678 · form4-12092024_101253.xml · nonDerivative · entry 1 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,327,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.95 | $697,450.00 |
DisclosureSEC source: 0001415889-24-027411 · form4-11212024_041104.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,198,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $13.949, and the range of prices were between $13.50 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.95 | $697,510.00 |
DisclosureSEC source: 0001415889-24-027411 · form4-11212024_041104.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,347,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $13.9502 and the range of prices were between $13.50 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 4,876 | $17.64 | $86,020.44 |
DisclosureSEC source: 0001415889-24-026866 · form4-11142024_041104.xml · nonDerivative · entry 5 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,248,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F7 · price: The weighted average sale price for the transaction reported was $17.6416, and the range of prices were between $17.42 and $17.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F6 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 45,124 | $16.76 | $756,296.29 |
DisclosureSEC source: 0001415889-24-026866 · form4-11142024_041104.xml · nonDerivative · entry 4 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,253,375 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · price: The weighted average sale price for the transaction reported was $16.7604, and the range of prices were between $16.40 and $17.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F6 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 4,955 | $17.64 | $87,421.07 |
DisclosureSEC source: 0001415889-24-026866 · form4-11142024_041104.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,296,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $17.643, and the range of prices were between $17.42 and $17.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 45,045 | $16.76 | $754,904.65 |
DisclosureSEC source: 0001415889-24-026866 · form4-11142024_041104.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,301,449 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $16.7589, and the range of prices were between $16.405 and $17.395. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $14.88 | $743,820.00 |
DisclosureSEC source: 0001415889-24-025368 · form4-10172024_041024.xml · nonDerivative · entry 4 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,298,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · price: The weighted average sale price for the transaction reported was $14.8764, and the range of prices were between $14.26 and $15.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F6 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,450 | $15.25 | $22,118.16 |
DisclosureSEC source: 0001415889-24-025368 · form4-10172024_041024.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,397,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $15.2539 and the range of prices were between $15.25 and $15.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 48,550 | $14.86 | $721,656.91 |
DisclosureSEC source: 0001415889-24-025368 · form4-10172024_041024.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,398,897 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $14.8642 and the range of prices were between $14.245 and $15.245. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:27 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.83 | $691,390.00 |
DisclosureSEC source: 0001415889-24-024980 · form4-10102024_081026.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,348,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $13.8278, and the range of prices were between $13.60 and $14.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:27 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $13.83 | $691,385.00 |
DisclosureSEC source: 0001415889-24-024980 · form4-10102024_081026.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,346,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $13.8277, and the range of prices were between $13.60 and $14.025. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:26 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $12.93 | $646,680.00 |
DisclosureSEC source: 0001415889-24-023709 · form4-09192024_080917.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,398,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $12.9336, and the range of prices were between $12.65 and $13.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:26 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $12.93 | $646,525.00 |
DisclosureSEC source: 0001415889-24-023709 · form4-09192024_080917.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,447,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.9305 and the range of prices were between $12.645 and $13.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 20:24 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.50 | $574,910.00 |
DisclosureSEC source: 0001415889-24-023290 · form4-09122024_080915.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,448,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $11.4982, and the range of prices were between $11.28 and $11.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 20:24 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.50 | $574,865.00 |
DisclosureSEC source: 0001415889-24-023290 · form4-09122024_080915.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,396,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $11.4973, and the range of prices were between $11.28 and $11.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,261 | $16.25 | $36,748.49 |
DisclosureSEC source: 0001415889-24-021877 · form4-08212024_100821.xml · nonDerivative · entry 7 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,498,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F9 · price: The weighted average sale price for the transaction report was $16.2532 and the range of prices were between $16.12 and $16.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F7 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 11,523 | $15.62 | $180,028.44 |
DisclosureSEC source: 0001415889-24-021877 · form4-08212024_100821.xml · nonDerivative · entry 6 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,500,760 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F8 · price: The weighted average sale price for the transaction report was $15.6234,and the range of prices were between $15.10 and $16.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F7 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 36,216 | $14.76 | $534,461.24 |
DisclosureSEC source: 0001415889-24-021877 · form4-08212024_100821.xml · nonDerivative · entry 5 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,512,283 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F6 · price: The weighted average sale price for the transaction report was $14.7576,and the range of prices were between $14.09 and $15.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F7 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,300 | $16.26 | $37,395.47 |
DisclosureSEC source: 0001415889-24-021877 · form4-08212024_100821.xml · nonDerivative · entry 4 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,497,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · price: The weighted average sale price for the transaction report was $16.2589 and the range of prices were between $16.15 and $16.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 11,756 | $15.61 | $183,545.25 |
DisclosureSEC source: 0001415889-24-021877 · form4-08212024_100821.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,499,747 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction report was $15.6129 and the range of prices were between $15.10 and $16.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 35,944 | $14.76 | $530,407.64 |
DisclosureSEC source: 0001415889-24-021877 · form4-08212024_100821.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,511,503 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction report was $14.7565 and the range of prices were between $14.09 and $15.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 35,363 | $12.77 | $451,440.52 |
DisclosureSEC source: 0001415889-24-021362 · form4-08152024_040805.xml · nonDerivative · entry 5 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,548,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F7 · price: The weighted average sale price for the transaction reported was $12.7659, and the range of prices were between $12.35 and $13.095. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F6 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 14,637 | $11.77 | $172,327.26 |
DisclosureSEC source: 0001415889-24-021362 · form4-08152024_040805.xml · nonDerivative · entry 4 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,583,862 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · price: The weighted average sale price for the transaction reported was $11.7734, and the range of prices were between $11.335 and $12.215. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F6 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 35,401 | $12.76 | $451,879.60 |
DisclosureSEC source: 0001415889-24-021362 · form4-08152024_040805.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,446,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $12.7646, and the range of prices were between $12.24 and $13.085. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 14,599 | $11.78 | $171,907.60 |
DisclosureSEC source: 0001415889-24-021362 · form4-08152024_040805.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,481,895 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $11.7753, and the range of prices were between $11.31 and $12.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.40 | $570,155.00 |
DisclosureSEC source: 0001415889-24-019770 · form4-07182024_040707.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,598,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $11.4031, and the range of prices were between $11.11 and $11.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $11.40 | $570,140.00 |
DisclosureSEC source: 0001415889-24-019770 · form4-07182024_040707.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,547,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $11.4028, and the range of prices were between $11.11 and $11.825. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 21:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.62 | $480,840.00 |
DisclosureSEC source: 0001415889-24-019493 · form4-07112024_090720.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,648,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $9.6168, and the range of prices were between $9.38 and $9.805. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 21:03 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.62 | $480,885.00 |
DisclosureSEC source: 0001415889-24-019493 · form4-07112024_090720.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,496,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $9.6177, and the range of prices were between $9.38 and $9.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 48,028 | $9.14 | $439,201.65 |
DisclosureSEC source: 0001415889-24-016678 · form4-06132024_040607.xml · nonDerivative · entry 5 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,698,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F7 · price: The weighted average sale price for the transaction reported was $9.1447, and the range of prices were between $9.01 and $9.315. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 47,834 | $9.15 | $437,461.06 |
DisclosureSEC source: 0001415889-24-016678 · form4-06132024_040607.xml · nonDerivative · entry 4 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,546,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F6 · price: The weighted average sale price for the transaction reported was $9.1454, and the range of prices were between $9.01 and $9.315. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,972 | $9.00 | $17,755.69 |
DisclosureSEC source: 0001415889-24-016678 · form4-06132024_040607.xml · nonDerivative · entry 3 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,746,527 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $9.0039, and the range of prices were between $9.00 and $9.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,166 | $9.00 | $19,498.33 |
DisclosureSEC source: 0001415889-24-016678 · form4-06132024_040607.xml · nonDerivative · entry 2 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,594,328 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $9.002, and the range of prices were between $9.00 and $9.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 44,350 | $9.06 | $401,709.00 |
DisclosureSEC source: 0001415889-24-013387 · form4-05162024_110552.xml · nonDerivative · entry 7 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,748,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F9 · price: The weighted average sale price for the transaction reported was $9.0577, and the range of prices were between $9.00 and $9.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 44,746 | $9.06 | $405,313.74 |
DisclosureSEC source: 0001415889-24-013387 · form4-05162024_110552.xml · nonDerivative · entry 6 Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,597,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F8 · price: The weighted average sale price for the transaction reported was $9.0581, and the range of prices were between $9.00 and $9.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.